Lexicon Pharmaceuticals LXRX Business Segments — Other segment expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's business segments — other segment expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's business segments — other segment expense?
- Lexicon Pharmaceuticals (LXRX) reported business segments — other segment expense of $3.08M in Q1 2026.
- How has Lexicon Pharmaceuticals's business segments — other segment expense changed year-over-year?
- Lexicon Pharmaceuticals's business segments — other segment expense increased by 9.9% year-over-year, from $2.8M to $3.08M.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — other segment expense?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — other segment expense has grown at a 1.8% compound annual growth rate (CAGR), from $11.82M to $12.48M.
- What does business segments — other segment expense mean?
- Miscellaneous operating costs associated with the segment that do not fall under standard categories like R&D or sales. This may include restructuring charges, legal settlements, or other non-recurring operational outflows. Tracking this helps investors identify hidden costs that impact the segment's bottom-line performance.